What did @drterrysimpson actually say?
Simpson's core argument is that grey-market peptides, sourced through what he calls "Jimbroughs" (gym bros), are dangerous because they bypass FDA manufacturing oversight, are likely produced in China or India under inferior conditions, and are classified as "research grade" meant for animals, not humans. He calls them "a scam" with "no validity behind them."
He also draws a useful distinction: some peptides, like insulin, are legitimate prescription drugs manufactured under strict FDA processes. His implicit point is that the prescription pathway exists for a reason. He's not anti-peptide. He's anti-unregulated-peptide. That's a meaningful difference that gets lost in the hot take format.
He also slides in a comparison to refusing ice on airplanes as a proxy for inconsistent risk tolerance. It's a bit of rhetorical theater, but the underlying logic holds.
Does the science back this up?
On the manufacturing and contamination risks, yes, the evidence is legitimately concerning. The FDA has repeatedly flagged compounded and grey-market peptides for purity and sterility failures.
A 2023 FDA analysis of compounded semaglutide products found that many samples contained incorrect dosages and undisclosed excipients. While that's a different peptide category than BPC-157 or TB-500, it illustrates the broader point: without cGMP oversight, you don't actually know what's in the vial.
Research on BPC-157 (body protection compound) is almost entirely preclinical. Studies in rodents, like those by Sikiric et al. published repeatedly in Current Pharmaceutical Design and Journal of Physiology, show interesting effects on tissue repair and gastric healing. But none of this has been replicated in rigorous human clinical trials. The jump from rat data to human injection is exactly the kind of leap Simpson is warning against.
TB-500, a synthetic fragment of thymosin beta-4, has similarly compelling animal data (Goldstein et al., 2012, Annals of the New York Academy of Sciences) but no peer-reviewed human RCTs demonstrating safety or efficacy at the doses being sold online.
What did they get wrong (or right)?
Simpson gets the safety architecture mostly right, but oversimplifies in ways that matter. Calling all grey-market peptides "a scam" and saying they have "no validity behind them" is too broad. Some of these compounds, particularly BPC-157 and thymosin alpha-1 analogs, have genuine research interest behind them. Dismissing the entire category as fraudulent ignores that the problem is primarily regulatory, not mechanistic.
He's also slightly off on the GLP framing. He mentions "GLP-3" which is not an established clinical designation. He likely means GLP-1 receptor agonists like semaglutide or tirzepatide. GLP-3 is referenced in some early gut peptide research but is not a recognized therapeutic class. This suggests either a slip or conflation of terms, which undercuts his authority slightly.
Where he's clearly right: the research-grade label is genuinely important. Research-grade peptides are not manufactured to human-use standards. They are not sterile tested to the same threshold. Injecting research-grade material carries infection and contamination risks that are not hypothetical.
What should you actually know?
The grey-market peptide space is not uniformly populated by scammers, but it is uniformly unregulated. That distinction matters for how you think about risk.
Some compounds like BPC-157 are available through licensed compounding pharmacies in the U.S. under physician supervision. That pathway, while still lacking large-scale RCT support, at least involves sterility testing, physician oversight, and some accountability. That is categorically different from buying lyophilized powder from an overseas vendor and reconstituting it yourself.
The FDA has issued warning letters to multiple peptide vendors. The National Institutes of Health lists BPC-157 as having insufficient human safety data. Anyone presenting grey-market injectable peptides as equivalent in safety to physician-prescribed compounded peptides is giving you a misleading picture.
- If you're interested in peptide therapy, the conversation starts with a licensed provider, not a supplement store or online vendor.
- "Research grade" is a real designation with real implications. It signals that a substance has not been manufactured or tested for human use.
- The absence of clinical trials does not mean something doesn't work. It means you don't know if it works, or at what cost.